Arcellx (ACLX) Revenue & Revenue Breakdown
Arcellx Revenue Highlights
Latest Revenue (Y)
$107.94M
Latest Revenue (Q)
$7.55M
Arcellx Revenue by Period
Arcellx Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $107.94M | -2.16% |
| 2023-12-31 | $110.32M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Arcellx generated $107.94M in revenue during NA 2024, up -2.16% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Arcellx Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $7.55M | -7.07% |
| 2025-03-31 | $8.13M | -46.75% |
| 2024-12-31 | $15.27M | -41.35% |
| 2024-09-30 | $26.03M | -4.94% |
| 2024-06-30 | $27.38M | -30.24% |
| 2024-03-31 | $39.26M | -37.83% |
| 2023-12-31 | $63.15M | 322.20% |
| 2023-09-30 | $14.96M | 4.58% |
| 2023-06-30 | $14.30M | -20.15% |
| 2023-03-31 | $17.91M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | - |
Arcellx generated $7.55M in revenue during Q2 2025, up -7.07% compared to the previous quarter, and up 19.24% compared to the same period a year ago.
Arcellx Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALKS | Alkermes | $1.56B | $394.19M |
| ARWR | Arrowhead Pharmaceuticals | $829.45M | $542.71M |
| ACLX | Arcellx | $107.94M | $7.55M |
| KYMR | Kymera Therapeutics | $47.07M | $2.76M |
| NAMS | NewAmsterdam Pharma | $45.56M | $19.14M |
| CRSP | CRISPR Therapeutics | $37.31M | $889.00K |
| AKRO | Akero Therapeutics | - | - |
| PTGX | Protagonist Therapeutics | - | - |
| VKTX | Viking Therapeutics | - | - |
| PCVX | Vaxcyte | - | - |
| IMVT | Immunovant | - | - |